IP Library Granted Patent US 10,940,230
Granted Patent B2
US 10,940,230 · App. 15/771,230 · Granted Mar 9, 2021

Chitosan-based hemostatic member for cervix and method of manufacturing the same

Inventor: Min Ho Jung (Daegu, KR)
Assignees: ENDOVISION CO., LTD.; Min Ho Jung
A61L15/28A61B17/12131A61F13/00008A61F13/36A61L24/0036A61L24/08A61B2017/00526A61B2017/12004A61B2017/4225A61B2090/3966A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,940,230
App. No.
15/771,230
Granted
Mar 9, 2021
Kind
B2
Abstract

This invention relates to a hemostatic member using chitosan having superior hemostatic activity, and more particularly to a chitosan-based hemostatic member for the cervix, suitable for use through insertion into an affected part upon cervical biopsy or surgery, configured to include a hemostatic pack having a projection at an upper end thereof through tying with a thread so as to form a spherical shape using chitosan nonwoven fabrics having a hemostatic function, wherein the thread contains an X-ray-sensitive material, thereby realizing effective hemostasis of the affected part upon cervical biopsy or surgery.

Claims (23)

1. A chitosan-based hemostatic member, comprising: (1) a hemostatic pack made of chitosan nonwoven fabrics formed in a spherical shape and having a projection at an upper end thereof, said projection the result of the chitosan nonwoven fabrics having been tied with a thread; and (2) peripheral pressing portions,

wherein the peripheral pressing portions comprise a non-chitosan nonwoven fabric or a chitosan nonwoven fabric in a form of a straight line connected to both sides of the projection,

the thread contains an X-ray-sensitive material and extends for connection to the peripheral pressing portions,

the nonwoven fabrics have a hemostatic function, and

the chitosan-based hemostatic member is suitable for use through insertion into an affected part of a cervix upon cervical biopsy or surgery.

2. The chitosan-based hemostatic member of claim 1 , wherein the thread connected to the peripheral pressing portions extends by passing through each of the peripheral pressing portions from inside the hemostatic pack.

3. A method of manufacturing the chitosan-based hemostatic member of claim 1 for a cervix, comprising:

preparing chitosan nonwoven fabrics composed of chitosan fibers; and

shaping the hemostatic pack having the spherical shape by stacking the chitosan nonwoven fabrics and subjecting edges thereof to gathering together and tying with the thread containing an X-ray-sensitive material so as to form a projection.

4. The method of claim 3 , comprising, after the shaping the hemostatic pack:

forming a CMCS coating layer on a surface of the hemostatic pack by immersing the hemostatic pack in a CMCS solution; and then

forming a CMCS sponge by covering an outer surface of the CMOS coating layer with the CMCS solution.

5. The method of claim 4 , wherein the forming the CMCS sponge comprises:

seating the hemostatic pack having the CMCS coating layer formed thereon in a shaping mold;

introducing the CMCS solution into the shaping mold;

lyophilizing the CMCS solution by placing the shaping mold in a lyophilizer to thus achieve an integration with the hemostatic pack; and

thermally treating a lyophilized body by applying heat thereto.

6. The method of claim 5 , wherein preliminary freezing is performed before the lyophilizing, and

the preliminary freezing is carried out in a manner in which the shaping mold is stabilized at 0-−5° C. for 1-2 hr and then immersed for 15 min to 30 min in ethanol cooled to −80° C. or less and thus instantly treated.

7. The method of claim 5 , wherein preliminary freezing is performed before the lyophilizing, and

the preliminary freezing is carried out in a manner in which the shaping mold is placed in the lyophilizer and stabilized in a supercooled state at 0° C.-− 5 ° C. for 2-3 hr and then treated at −30° C.-−40° C. for 3-4 hr.

8. The method of claim 4 , wherein the CMCS solution is prepared by dissolving 3-5% CMCS in distilled water, adding 1-3% glycerin thereto, and performing stirring for 2 hr or more.

9. The method of claim 8 , wherein the CMCS solution obtained through stirring is filtered using a mesh filter so as to increase purity, and is stored at 2-4° C. so as to be defoamed.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2018
From: JUNG, MIN HO
To: ENDOVISION CO., LTD.; JUNG, MIN HO
Reel/Frame 045647/0572 →
Priority Claims (1)
KR 10-2017-0127526 · Sep 29, 2017 · national
Continuity (1)
Related Publication 20190099512A1 · Apr 4, 2019